FDA Approved: DARZALEX — Supplemental Application (Janssen Biotech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for DARZALEX (daratumumab) submitted by Janssen Biotech, Inc. to modify/expand the approved use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis
• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)

Snippet

SUPPL AP for DARZALEX (DARATUMUMAB)